N/A
Completed N=167
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
Severe Acute Respiratory Syndrome · Ventilation Pneumonitis
Source: ClinicalTrials.gov NCT04425863 ↗
Enrolled (actual)
167
Serious AEs
0.6%
Results posted
Oct 2020
Primary outcomePrimary: Patients Who Improved Their Condition or Did Not Worsen it — 135; 12; 19 Participants
Summary
The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patients Who Improved Their Condition or Did Not Worsen it |
135; 12; 19 | — |
| PRIMARY ICU-treated Patients After 2-week Treatment |
0; 0; 2 | — |
| PRIMARY Mortality |
0; 0; 1 | 0.0246 sig |
| PRIMARY Patients Needing Drug Dose Adjustment |
0; 0; 0 | — |
| PRIMARY Adverse Events |
0; 0; 1 | — |
Eligibility Criteria
Inclusion Criteria
patients with positive oral/nasal swabs
Exclusion Criteria
Children under 5 years old Pregnant women Previous reports of allergy to any of the drugs used in the clinical trial
Data sourced from ClinicalTrials.gov (NCT04425863). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.